Table 11.
Phase III ongoing trials assessing anti-FXI drugs in the prevention of thrombosis.
| Compound Name | Inhibitory Class | Setting | Trial ID | Regimen | Comparator | Sample Size | Status |
|---|---|---|---|---|---|---|---|
| Abelacimab (MAA868) | Fully human mAb IgG1 | Cancer-associated thrombosis |
NCT05171075 (Magnolia) |
IV/SC | Dalteparin | 1020 | Recruiting |
| Abelacimab (MAA868) | Fully human mAb IgG1 | Cancer-associated thrombosis |
NCT05171049 (Aster) |
IV/SC | Apixaban | 1655 | Recruiting |
| Asundexian (BAY 2433334) |
Small molecule | Atrial fibrillation at risk for stroke | OCEANIC-AF | Oral | Apixaban | ~2000 | Upcoming |
| Asundexian (BAY 2433334) |
Small molecule | Non-cardioembolic ischemic stroke or high-risk ischemic attack | OCEANIC-Stroke | Oral | placebo-controlled study on top of standard-of-care antiplatelet therapy | ~2000 | Upcoming |